CL2020001346A1 - Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción. - Google Patents
Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción.Info
- Publication number
- CL2020001346A1 CL2020001346A1 CL2020001346A CL2020001346A CL2020001346A1 CL 2020001346 A1 CL2020001346 A1 CL 2020001346A1 CL 2020001346 A CL2020001346 A CL 2020001346A CL 2020001346 A CL2020001346 A CL 2020001346A CL 2020001346 A1 CL2020001346 A1 CL 2020001346A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrimidinylamino
- polymorphs
- production
- methods
- solid forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
La presente descripción hace referencia a formas amorfas y polimórficas cristalinas de 2-metil-2-(3-metil-4-(4-(metilamino)-5-(trifluorometil)pirimidin-2-ilamino)-1H-pirazol-1-il)propanonitrilo o solvatos, tautómeros y cocristales o sales farmacéuticamente aceptables de este, así como a procesos para su elaboración.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762589276P | 2017-11-21 | 2017-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001346A1 true CL2020001346A1 (es) | 2020-11-20 |
Family
ID=66631734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001346A CL2020001346A1 (es) | 2017-11-21 | 2020-05-21 | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción. |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10370361B2 (es) |
| EP (1) | EP3717473B1 (es) |
| JP (1) | JP7303821B2 (es) |
| KR (1) | KR20200089713A (es) |
| CN (1) | CN111819174A (es) |
| AR (1) | AR113893A1 (es) |
| AU (1) | AU2018372180B2 (es) |
| BR (1) | BR112020010215A2 (es) |
| CA (1) | CA3083022A1 (es) |
| CL (1) | CL2020001346A1 (es) |
| CO (1) | CO2020006206A2 (es) |
| CR (1) | CR20200216A (es) |
| EA (1) | EA202091279A1 (es) |
| IL (1) | IL274824A (es) |
| JO (1) | JOP20200128A1 (es) |
| MA (1) | MA51222A (es) |
| MX (1) | MX2020005332A (es) |
| PE (1) | PE20210157A1 (es) |
| SG (1) | SG11202004733WA (es) |
| TW (1) | TWI823878B (es) |
| UA (1) | UA126414C2 (es) |
| WO (1) | WO2019104086A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR113893A1 (es) | 2017-11-21 | 2020-06-24 | Denali Therapeutics Inc | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción |
| JP7284172B2 (ja) | 2017-12-20 | 2023-05-30 | デナリ セラピューティクス インコーポレイテッド | ピリミジニル－４－アミノピラゾール化合物の調製方法 |
| WO2023174946A1 (en) | 2022-03-15 | 2023-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Early and non-invasive method for assessing a subject's risk of having parkinson's disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102303885B1 (ko) | 2010-05-21 | 2021-09-24 | 인사이트 홀딩스 코포레이션 | Ｊａｋ 저해제에 대한 국소 제형 |
| MX2012014158A (es) | 2010-06-04 | 2013-02-07 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2). |
| GB201015949D0 (en) | 2010-09-22 | 2010-11-03 | Medical Res Council Technology | Compounds |
| HUE037844T2 (hu) * | 2010-11-10 | 2018-09-28 | Genentech Inc | Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok |
| MX349556B (es) | 2011-11-29 | 2017-08-03 | Genentech Inc | Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2). |
| AR089182A1 (es) | 2011-11-29 | 2014-08-06 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de lrrk2 |
| RU2651544C2 (ru) | 2011-11-29 | 2018-04-20 | Дженентек, Инк. | Производные аминопиримидина в качестве модуляторов богатой лейцином повторной киназы 2 (lrrk2) |
| PT2785711T (pt) | 2011-11-29 | 2016-09-30 | Hoffmann La Roche | Derivados de 2-(fenil ou pirid-3- il)aminopiridinacomo moduladores de lrrk2 quinase, para o tratamento da doença de parkinson |
| WO2013164323A1 (en) | 2012-05-03 | 2013-11-07 | F. Hoffmann-La Roche Ag | Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease |
| JP6218808B2 (ja) | 2012-05-03 | 2017-10-25 | ジェネンテック， インコーポレイテッド | Ｌｒｒｋ２モジュレ−タ−としてのピラゾ−ルアミノピリミジン誘導体 |
| WO2017218843A1 (en) * | 2016-06-16 | 2017-12-21 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders |
| AR113893A1 (es) * | 2017-11-21 | 2020-06-24 | Denali Therapeutics Inc | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción |
-
2018
- 2018-11-20 AR ARP180103389A patent/AR113893A1/es unknown
- 2018-11-20 CN CN201880081321.5A patent/CN111819174A/zh active Pending
- 2018-11-20 TW TW107141257A patent/TWI823878B/zh active
- 2018-11-20 PE PE2020000558A patent/PE20210157A1/es unknown
- 2018-11-20 MX MX2020005332A patent/MX2020005332A/es unknown
- 2018-11-20 EP EP18881859.5A patent/EP3717473B1/en active Active
- 2018-11-20 CA CA3083022A patent/CA3083022A1/en active Pending
- 2018-11-20 UA UAA202003681A patent/UA126414C2/uk unknown
- 2018-11-20 BR BR112020010215-6A patent/BR112020010215A2/pt unknown
- 2018-11-20 WO PCT/US2018/062102 patent/WO2019104086A1/en active Application Filing
- 2018-11-20 KR KR1020207017598A patent/KR20200089713A/ko not_active Application Discontinuation
- 2018-11-20 EA EA202091279A patent/EA202091279A1/ru unknown
- 2018-11-20 MA MA051222A patent/MA51222A/fr unknown
- 2018-11-20 SG SG11202004733WA patent/SG11202004733WA/en unknown
- 2018-11-20 JP JP2020545076A patent/JP7303821B2/ja active Active
- 2018-11-20 US US16/197,037 patent/US10370361B2/en active Active
- 2018-11-20 JO JOP/2020/0128A patent/JOP20200128A1/ar unknown
- 2018-11-20 CR CR20200216A patent/CR20200216A/es unknown
- 2018-11-20 AU AU2018372180A patent/AU2018372180B2/en active Active
-
2019
- 2019-06-20 US US16/447,713 patent/US10851088B2/en active Active
-
2020
- 2020-05-20 IL IL274824A patent/IL274824A/en unknown
- 2020-05-21 CL CL2020001346A patent/CL2020001346A1/es unknown
- 2020-05-21 CO CONC2020/0006206A patent/CO2020006206A2/es unknown
- 2020-11-27 US US17/105,870 patent/US11427571B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3083022A1 (en) | 2019-05-31 |
| EA202091279A1 (ru) | 2020-08-19 |
| AU2018372180A1 (en) | 2020-06-18 |
| EP3717473B1 (en) | 2024-01-10 |
| US20210087176A1 (en) | 2021-03-25 |
| US11427571B2 (en) | 2022-08-30 |
| UA126414C2 (uk) | 2022-09-28 |
| CO2020006206A2 (es) | 2020-08-10 |
| JOP20200128A1 (ar) | 2020-05-21 |
| US20190315723A1 (en) | 2019-10-17 |
| KR20200089713A (ko) | 2020-07-27 |
| CN111819174A (zh) | 2020-10-23 |
| PE20210157A1 (es) | 2021-01-26 |
| US20190194170A1 (en) | 2019-06-27 |
| IL274824A (en) | 2020-07-30 |
| JP7303821B2 (ja) | 2023-07-05 |
| EP3717473A1 (en) | 2020-10-07 |
| BR112020010215A2 (pt) | 2020-11-03 |
| CR20200216A (es) | 2021-03-19 |
| SG11202004733WA (en) | 2020-06-29 |
| MA51222A (fr) | 2020-10-07 |
| WO2019104086A1 (en) | 2019-05-31 |
| EP3717473A4 (en) | 2021-07-07 |
| TWI823878B (zh) | 2023-12-01 |
| MX2020005332A (es) | 2021-01-08 |
| AU2018372180B2 (en) | 2023-08-17 |
| TW201925190A (zh) | 2019-07-01 |
| JP2021504450A (ja) | 2021-02-15 |
| AR113893A1 (es) | 2020-06-24 |
| US10370361B2 (en) | 2019-08-06 |
| US10851088B2 (en) | 2020-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20170087A7 (es) | Formas cristalinas de 5-(4-ciclopropil-1 h-imidazol-1-il)-n-(6-(4-isopropil-4h-1 , 2, 4- triazol-3-il)piridin-2-il)-2-fluoro-4-metilbenzamida | |
| CL2020001346A1 (es) | Polimorfos y formas sólidas de un compuesto de pirimidinilamino-pirazol y métodos de producción. | |
| DOP2016000281A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| CO2017001884A2 (es) | Polimorfos de selinexor | |
| EA201791305A1 (ru) | Конденсированные пиримидины для лечения вич | |
| CU20160188A7 (es) | Compuestos de indazole substituidos como inhibidores de irak4 | |
| ECSP16067303A (es) | Heteroarilos y usos de estos | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| MD3882250T2 (ro) | Tetrahidropiranil-amino-pirolopirimidinona pentru utilizare într-un procedeu de tratament al unei tulburări mediate de BTK | |
| AR100818A1 (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| CL2021000276A1 (es) | Polimorfo cristalino del clorhidrato de 8-bromo-2-(1-metilpiperidin-4-ilamin)-4-(4-fenoxifenilamin)pirido[4,3-d]pirimidin-5(6h)-ona y método para prepararlo. | |
| UY38233A (es) | Agentes inhibidores para la tirosina cinasa de bruton | |
| CO2020012574A2 (es) | Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida | |
| AR099766A1 (es) | Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos | |
| CO2019008110A2 (es) | Activador de nrf2 | |
| MX2020004050A (es) | Intermediario cristalino de linagliptina y proceso para la preparacion de linagliptina. | |
| DOP2015000299A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| BR112018012095A2 (pt) | formas sólidas de compostos substituidos de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina | |
| CU24518B1 (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina | |
| AR101951A1 (es) | Síntesis de ent-progesterona e intermediarios de la misma |